Serine supplement to protect vision in MacTel type 2
Part of Eyes & vision clinical trials.
This study tests whether taking a daily serine supplement can help slow vision loss in people with MacTel type 2, a condition that affects the retina. If you qualify, you'll take the supplement or a placebo and have regular eye check-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with MacTel type 2 in at least one eye.
- Your vision in the study eye is 20/100 or better (with glasses or contacts).
- You can fast for 10 hours before blood tests.
- You agree to use effective birth control if you could become pregnant.
- You have not taken serine or glycine supplements in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This study is testing whether shining a special light on the eye, called photobiomodulation, can help people with dry age-related macular degeneration (AMD). If you have dry AMD and are willing to participate, you will receive the light treatment and be monitored.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This trial tests a new way to deliver lutein, a nutrient that may help with eye health, directly into the eye using a mild electrical current (called iontophoresis). It is for people with intermediate age-related macular degeneration (AMD), a common cause of vision loss in older adults.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Hear when a new Macular Telangiectasia Type 2 (MacTel) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.